Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Expenses (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Operating Expenses for 11 consecutive years, with $79.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 206.43% to $79.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $146.2 million through Dec 2025, up 76.55% year-over-year, with the annual reading at $146.2 million for FY2025, 76.55% up from the prior year.
  • Operating Expenses for Q4 2025 was $79.6 million at Cartesian Therapeutics, up from $21.5 million in the prior quarter.
  • The five-year high for Operating Expenses was $79.6 million in Q4 2025, with the low at $18.0 million in Q3 2024.
  • Average Operating Expenses over 5 years is $26.4 million, with a median of $23.1 million recorded in 2022.
  • The sharpest move saw Operating Expenses crashed 41.76% in 2024, then soared 206.43% in 2025.
  • Over 5 years, Operating Expenses stood at $25.9 million in 2021, then dropped by 2.2% to $25.3 million in 2022, then soared by 76.34% to $44.6 million in 2023, then plummeted by 41.76% to $26.0 million in 2024, then skyrocketed by 206.43% to $79.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $79.6 million, $21.5 million, and $22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.